B. Kerem

B. Kerem, J. Towbin, B. Attali, 2005, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

Variable Expression of Long QT Syndrome Among Gene Carriers from Families with Five Different HERG Mutations

B. Kerem, E. Kaufman, S. Priori, 2001, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

Identification andRegional Localization ofDNA Markers on Chromosome7fortheCloning oftheCystic Fibrosis Gene

B. Kerem, R. Rozmahel, N. Plavsic, 1988 .

Genomic Instability in Human Pluripotent Stem Cells Arises from Replicative Stress and Chromosome Condensation Defects.

B. Kerem, N. Benvenisty, Z. Storchová, 2016, Cell stem cell.

Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849 + 10 kb C-to-T splicing mutation

B. Kerem, L. Carmel, E. Kerem, 2021, bioRxiv.

Screening of CFTR mutations in an isolated population: identification of carriers and patients

B. Kerem, O. Chiba-Falek, M. Nissim-Rafinia, 1998, European Journal of Human Genetics.

Physical localization of two DNA markers closely linked to the cystic fibrosis locus by pulsed-field gel electrophoresis.

L. Tsui, J. Rommens, B. Kerem, 1989, American journal of human genetics.

Population diversity and distinct haplotype frequencies associated with ACHE and BCHE genes of Israeli Jews from trans-Caucasian Georgia and from Europe.

B. Kerem, H. Soreq, D. Glick, 1994, Genomics.

An interstitial nucleolus organizer region in the long arm of human chromosome 7: cytogenetic characterization and familial segregation

B. Kerem, C. Steinlein, M. Schmid, 1998, Cytogenetic and Genome Research.

Fragile sites are preferential targets for integrations of MLV vectors in gene therapy

B. Kerem, M. Cavazzana‐Calvo, A. Bester, 2006, Gene Therapy.

Nonsense-mediated mRNA decay and cystic fibrosis.

B. Kerem, Liat Linde, 2011, Methods in molecular biology.

Highly variable incidence of cystic fibrosis and different mutation distribution among different Jewish ethnic groups in Israel

C. Springer, B. Kerem, H. Blau, 1995, Human Genetics.

Cost-benefit analysis of a national screening programme for cystic fibrosis in an Israeli population.

C. Springer, B. Kerem, H. Blau, 1994, Health economics.

Nucleotide Deficiency Promotes Genomic Instability in Early Stages of Cancer Development

B. Kerem, A. Bensimon, A. Bester, 2011, Cell.

Cytological evidence of defective template in the fragile X chromosome

B. Kerem, T. Schaap, R. Goitein, 2004, Chromosoma.

Consensus on the Use and Interpretation of Cystic Fibrosis Mutation Analysis in Clinical Practice

B. Kerem, J. Zieleński, P. Pignatti, 2022 .

Identification of the Cystic Fibrosis Gene : Chromosome Walking and Jumping Author ( s ) :

J. Riordan, J. Rommens, B. Kerem, 2008 .

LRRC6 Mutation Causes Primary Ciliary Dyskinesia with Dynein Arm Defects

B. Kerem, S. Dutcher, S. Brody, 2013, PloS one.

Congenital bilateral absence of vas deferens in the absence of cystic fibrosis

B. Kerem, Eran Gazit, A. Augarten, 1994, The Lancet.

Mutation analysis for heterozygote detection and the prenatal diagnosis of cystic fibrosis.

L. Tsui, F. Collins, A. Beaudet, 1990, The New England journal of medicine.

The Molecular Basis for Disease Variability in Cystic Fibrosis

B. Kerem, E. Kerem, 1996, European journal of human genetics : EJHG.

Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.

B. Kerem, H. Blau, Z. Bebők, 2003, The New England journal of medicine.

The molecular basis of partial penetrance of splicing mutations in cystic fibrosis.

B. Kerem, A. Darvasi, M. Nissim-Rafinia, 1997, American journal of human genetics.

Introducing sense into nonsense in treatments of human genetic diseases.

B. Kerem, Liat Linde, 2008, Trends in genetics : TIG.

The relationship between genotype and phenotype in cystic fibrosis.

B. Kerem, E. Kerem, 1995, Current opinion in pulmonary medicine.

Oncogene-Induced Replication Stress Drives Genome Instability and Tumorigenesis

B. Kerem, Dan Sarni, 2017, International Journal of Molecular Sciences.

Kerem, Arie, Eitan, 2013 .

Extended haplotype analysis of cystic fibrosis mutations and its implications for the selective advantage hypothesis

B. Kerem, T. Shoshani, N. Bashan, 1993, Human Genetics.

A missense cystic fibrosis transmembrane conductance regulator mutation with variable phenotype.

M. Corey, B. Kerem, M. Nissim-Rafinia, 1997, Pediatrics.

B. Kerem, E. Kerem, T. Shoshani, 1994, The Journal of clinical investigation.

AT-dinucleotide rich sequences drive fragile site formation

B. Kerem, Yuh-Hwa Wang, A. Weiss, 2019, Nucleic acids research.

Genomic instability in fragile sites—still adding the pieces

B. Kerem, M. Irony-Tur Sinai, 2018, Genes, chromosomes & cancer.

DNA replication stress drives fragile site instability.

B. Kerem, M. Irony-Tur Sinai, 2017, Mutation research.

Failure of origin activation in response to fork stalling leads to chromosomal instability at fragile sites.

B. Kerem, R. Lebofsky, A. Bensimon, 2011, Molecular cell.

Homologous recombination and nonhomologous end-joining repair pathways regulate fragile site stability.

David J. Chen, Benjamin P. C. Chen, B. Kerem, 2005, Genes & development.

Molecular Basis for Expression of Common and Rare Fragile Sites

S. Scherer, B. Kerem, H. Margalit, 2003, Molecular and Cellular Biology.

Replication Delay along FRA7H, a Common Fragile Site on Human Chromosome 7, Leads to Chromosomal Instability

Stephen W. Scherer, S. Scherer, L. Tsui, 2000, Molecular and Cellular Biology.

The molecular basis of common and rare fragile sites.

B. Kerem, Eitan Zlotorynski, M. Schwartz, 2006, Cancer letters.

Common fragile sites: G-band characteristics within an R-band.

B. Kerem, H. Margalit, Y. Mandel-Gutfreund, 1999, American journal of human genetics.

Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations.

B. Kerem, O. Chiba-Falek, M. Nissim-Rafinia, 2000, Human molecular genetics.

Absence of a paternally inherited FOXP2 gene in developmental verbal dyspraxia.

Wendy Roberts, Juha Kere, Lars Feuk, 2006, American journal of human genetics.

Regions of active chromatin conformation in ‘inactive’ male meiotic sex chromosomes of the mouse

B. Kerem, C. Richler, J. Wahrman, 2004, Chromosoma.

Mapping of DNAase I sensitive regions on mitotic chromosomes

B. Kerem, H. Cedar, M. Marcus, 1984, Cell.

A role for common fragile site induction in amplification of human oncogenes.

David I. Smith, S. Scherer, J. Vincent, 2002, Cancer cell.

The presence of extra chromosomes leads to genomic instability

B. Kerem, W. Kloosterman, Z. Storchová, 2016, Nature Communications.

Molecular and Cellular Pathobiology Transcriptional Dynamics in Colorectal Carcinogenesis : New Insights into the Role of c-Myc and miR 17 in Benign to Cancer Transformation

B. Kerem, E. Ben-David, S. Shifman, 2014 .

Incidence and expression of the N1303K mutation of the cystic fibrosis (CFTR) gene

X. Estivill, K. Klinger, B. Kerem, 1992, Human Genetics.

Folate levels modulate oncogene-induced replication stress and tumorigenicity

B. Kerem, R. Karni, A. Bester, 2015, EMBO molecular medicine.

Two novel mutations in the CFTR gene: W1089X in exon 17B and 4010delTATT in exon 21.

B. Kerem, T. Shoshani, E. Gazit, 1994, Human molecular genetics.

Correlation between genotype and phenotype in patients with cystic fibrosis.

B. Kerem, E. Kerem, E. Gazit, 1994, The New England journal of medicine.

New approaches to genetic therapies for cystic fibrosis.

B. Kerem, Shuling Guo, S. Hart, 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Genotype‐phenotype correlations in cystic fibrosis

B. Kerem, E. Kerem, 1996, Pediatric pulmonology.

The complex basis underlying common fragile site instability in cancer.

B. Kerem, A. Bester, E. Ozeri-Galai, 2012, Trends in genetics : TIG.

Infection with retroviral vectors leads to perturbed DNA replication increasing vector integrations into fragile sites

B. Kerem, Moshe Kafri, A. Bester, 2013, Scientific Reports.

Impaired Replication Stress Response in Cells from Immunodeficiency Patients Carrying Cernunnos/XLF Mutations

B. Kerem, A. Rahat, S. Yitzchaik, 2009, PloS one.

Human Chromosome 7: DNA Sequence and Biology

Junjun Zhang, Nazneen Rahman, Alexander K. Hudek, 2003, Science.

The complex nature of fragile site plasticity and its importance in cancer.

B. Kerem, Dan Sarni, 2016, Current opinion in cell biology.

Interplay between genetic and epigenetic factors governs common fragile site instability in cancer

B. Kerem, A. Bester, E. Ozeri-Galai, 2014, Cellular and Molecular Life Sciences.

3D genome organization contributes to genome instability at fragile sites

B. Kerem, D. Gilbert, J. Rivera-Mulia, 2020, Nature Communications.

Molecular characterization of a common fragile site (FRA7H) on human chromosome 7 by the cloning of a simian virus 40 integration site.

S. Scherer, L. Tsui, B. Kerem, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Genome scan of Arab Israeli families maps a schizophrenia susceptibility gene to chromosome 6q23 and supports a locus at chromosome 10q24

B. Kerem, K. Kanyas, B. Lerer, 2003, Molecular Psychiatry.

Selected bibliography of Susumu Ohno

C. Disteche, B. Migeon, B. Kerem, 1998, Cytogenetic and Genome Research.

Topoisomerase 1-dependent R-loop deficiency drives accelerated replication and genomic instability

B. Kerem, Y. Oren, Alon Shtrikman, 2020, Cell reports.

Topoisomerase 1 dependent R-loop deficiency as a mechanism underlying oncogene-induced replication stress and genomic instability

B. Kerem, Y. Oren, Alon Shtrikman, 2020, bioRxiv.

The changing face of the exocrine pancreas in cystic fibrosis: the correlation between pancreatic status, pancreatitis and cystic fibrosis genotype

B. Kerem, H. Blau, M. Wilschanski, 2008, European journal of gastroenterology & hepatology.

Splicing modulation as a modifier of the CFTR function.

B. Kerem, M. Nissim-Rafinia, 2006, Progress in molecular and subcellular biology.

The molecular basis of disease variability among cystic fibrosis patients carrying the 3849+10 kb C-->T mutation.

B. Kerem, O. Chiba-Falek, E. Kerem, 1998, Genomics.

Identification and regional localization of DNA markers on chromosome 7 for the cloning of the cystic fibrosis gene.

J. Rommens, B. Kerem, R. Rozmahel, 1988, American journal of human genetics.

The splicing machinery is a genetic modifier of disease severity.

B. Kerem, M. Nissim-Rafinia, 2005, Trends in genetics : TIG.

Interplay between ATM and ATR in the regulation of common fragile site stability

B. Kerem, A. Rahat, M. Schwartz, 2008, Oncogene.

Intra- and extragenic marker haplotypes of CFTR mutations in cystic fibrosis families

K. Klinger, L. Tsui, B. Kerem, 1992, Human Genetics.

DNA amplification for detection of the XV-2c polymorphism linked to cystic fibrosis.

L. Tsui, A. Beaudet, J. Rommens, 1989, Nucleic acids research.

FRA18C: a new aphidicolin-inducible fragile site on chromosome 18q22, possibly associated with in vivo chromosome breakage

B. Kerem, D. Fitzpatrick, B. Winnepenninckx, 2007, Journal of Medical Genetics.

Cystic fibrosis in Jews: frequency and mutation distribution.

B. Kerem, O. Chiba-Falek, E. Kerem, 1997, Genetic testing.

Replication Timing and Transcription Identifies a Novel Fragility Signature Under Replication Stress

B. Kerem, D. Gilbert, J. Rivera-Mulia, 2019, bioRxiv.

Protein electrophoretic markers in Israel: compilation of data and genetic affinities

B. Kerem, L. Peleg, M. Shohat, 2002, Annals of human biology.

A new mutation in the CFTR gene, composed of two adjacent DNA alterations, is a common cause of cystic fibrosis among Georgian Jews.

B. Kerem, E. Kerem, T. Shoshani, 1993, Genomics.

Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis.

J. Lueck, B. Kerem, N. Allaire, 2023, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial

Eitan Kerem, B. Kerem, H. Blau, 2008, The Lancet.

The efficiency of nonsense-mediated mRNA decay is an inherent character and varies among different cells

B. Kerem, G. Neu-Yilik, A. Kulozik, 2007, European Journal of Human Genetics.

Identification of Dormancy-Associated MicroRNAs for the Design of Osteosarcoma-Targeted Dendritic Polyglycerol Nanopolyplexes.

B. Kerem, N. Shomron, I. Barshack, 2016, ACS nano.

High prevalence of W1282x mutation in cystic fibrosis patients from Karachay-Cherkessia.

B. Kerem, E. Ginter, A. Voronkova, 2016, Journal of Cystic Fibrosis.

Deletion and Insertion Mutations in Short Tandem Repeats in the Coding Regions of Human Genes

B. Kerem, A. Darvasi, 1995, European journal of human genetics : EJHG.

Take it personally: how personal we reach when we are so different from each other?

B. Kerem, E. Kerem, Y. Oren, 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

The suppression of premature termination codons and the repair of splicing mutations in CFTR

B. Kerem, I. Sermet-Gaudelus, I. Pranke, 2017, Current opinion in pharmacology.

PTC124 for cystic fibrosis – Authors' reply

B. Kerem, S. Peltz, E. Kerem, 2009, The Lancet.

119 Fork stalling at AT-rich sequences and failure of origin activation lead to chromosomal instability at fragile sites

B. Kerem, E. Ozeri-Galai, M. Sinai, 2013 .

Oncogenes create a unique landscape of fragile sites

B. Kerem, E. Ben-David, T. Golan-lev, 2015, Nature Communications.

The significance of sweat Cl/Na ratio in patients with borderline sweat test

Eitan Kerem, B. Kerem, E. Kerem, 1995, Pediatric pulmonology.

Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation

B. Kerem, S. Randell, O. Chiba-Falek, 2004, EMBO reports.

Automatic Detection of Combed DNA

B. Kerem, A. Weiss, E. Ozeri-Galai, 2010 .

Serum CA 19–9 levels as a diagnostic marker in cystic fibrosis patients with borderline sweat tests

B. Kerem, H. Blau, E. Kerem, 2003, Clinical and Experimental Medicine.

Identification of mutations in exons 1 through 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

L. Tsui, J. Rommens, B. Kerem, 1991, Genomics.

DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis.

M. Corey, L. Tsui, J. Rommens, 1989, American journal of human genetics.

Developmental Dyscalculia Is a Familial Learning Disability

O Manor, B. Kerem, Y. Friedlander, 2001, Journal of learning disabilities.

Evidence of genetic heterogeneity in the long QT syndrome.

B. Kerem, J. Blangero, J. Towbin, 1993, Science.

Continuous chromosomal instability in human pluripotent stem cells – the role of DNA replication

B. Kerem, Noa Lamm, 2016, Molecular & cellular oncology.

Novel LQT-3 Mutation Affects Na+ Channel Activity Through Interactions Between α- and β1-Subunits

B. Kerem, R. Kass, J. Benhorin, 1998 .

Mutation analysis in cystic fibrosis.

L. Tsui, F. Collins, A. Beaudet, 1990, The New England journal of medicine.

Interplay between genetic and epigenetic factors governs common fragile site instability in cancer

B. Kerem, A. Bester, E. Ozeri-Galai, 2014, Cellular and Molecular Life Sciences.

To break or not to break – context matters

B. Kerem, K. Miron, 2016, Molecular & cellular oncology.

Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide

B. Kerem, C. Stampfer, D. Hill, 2023, medRxiv.

Methods for analysis of multiple cystic fibrosis mutations

L. Tsui, A. Beaudet, B. Kerem, 1991, Human Genetics.

Serum lipase levels pre and post Landh meal: Evaluation of exocrine pancreatic status in cystic fibrosis

B. Kerem, J. Sack, A. Lusky, 1998, International journal of clinical & laboratory research.

Nonsense mutations accelerate lung disease and decrease survival of cystic fibrosis children.

B. Kerem, P. Reix, P. Burgel, 2023, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

The CFTR Gene: Structure, Mutations and Specific Therapeutic Approaches

B. Kerem, M. Nissim-Rafinia, Liat Linde, 2006 .

Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.

B. Kerem, E. Kerem, F. Ratjen, 2023, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease.

B. Kerem, E. Kerem, T. Shoshani, 1992, American journal of human genetics.

Cystic fibrosis mutations in North American populations of French ancestry: analysis of Quebec French-Canadian and Louisiana Acadian families.

K. Klinger, L. Tsui, B. Kerem, 1990, American Journal of Human Genetics.

DNase I sensitivity of Microtus agrestis active, inactive and reactivated X chromosomes in mouse-Microtus cell hybrids

B. Kerem, K. Sperling, V. Kalscheuer, 2004, Chromosoma.

Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

L. Tsui, F. Collins, J. Riordan, 1989, Science.

Identification of the cystic fibrosis gene: genetic analysis.

L. Tsui, J. Rommens, B. Kerem, 1989, Science.

Endoreduplication and polyploidy in fragile X cells induced by methotrexate and fluorodeoxyuridine: implications for diagnosis.

B. Kerem, C. Kimchi-Sarfaty, T. Schaap, 1991, American journal of medical genetics.

Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

B. Kerem, J. Zieleński, P. Pignatti, 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Recommendations for the classification of diseases as CFTR-related disorders.

B. Kerem, J. Zieleński, P. Pignatti, 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.